Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALA for Visualization of Malignant Glial Tumors
NCT01351519Phase 2Terminated
- Sponsor
- MultiCare Institute for Research & Innovation
- Start
- May 2011
- Primary completion
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of 5-aminolevulinic acid in malignant glioma, sponsored by MultiCare Institute for Research & Innovation. Primary endpoints: Time to disease progression after initial surgery up to 2 years and Complete Resection at Day 2. Started May 2011; status: terminated.
02
Drugs
5-aminolevulinic acid
03
Conditions
malignant glioma
Beyond the preview
Go deeper on NCT01351519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01351519.